[go: up one dir, main page]

AU2003230834A8 - Antagonists of il-21 and modulation of il-21-mediated t cell responses - Google Patents

Antagonists of il-21 and modulation of il-21-mediated t cell responses

Info

Publication number
AU2003230834A8
AU2003230834A8 AU2003230834A AU2003230834A AU2003230834A8 AU 2003230834 A8 AU2003230834 A8 AU 2003230834A8 AU 2003230834 A AU2003230834 A AU 2003230834A AU 2003230834 A AU2003230834 A AU 2003230834A AU 2003230834 A8 AU2003230834 A8 AU 2003230834A8
Authority
AU
Australia
Prior art keywords
antagonists
mediated
modulation
cell responses
responses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003230834A
Other versions
AU2003230834A1 (en
Inventor
Terry B Strom
Xin Xiao Zheng
Thomas Moll
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of AU2003230834A8 publication Critical patent/AU2003230834A8/en
Publication of AU2003230834A1 publication Critical patent/AU2003230834A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003230834A 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses Abandoned AU2003230834A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37103802P 2002-04-09 2002-04-09
US60/371,038 2002-04-09
PCT/US2003/010736 WO2003087320A2 (en) 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses

Publications (2)

Publication Number Publication Date
AU2003230834A8 true AU2003230834A8 (en) 2003-10-27
AU2003230834A1 AU2003230834A1 (en) 2003-10-27

Family

ID=29250623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003230834A Abandoned AU2003230834A1 (en) 2002-04-09 2003-04-08 Antagonists of il-21 and modulation of il-21-mediated t cell responses

Country Status (2)

Country Link
AU (1) AU2003230834A1 (en)
WO (1) WO2003087320A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233888D1 (en) 2001-11-05 2009-11-12 Zymogenetics Inc IL-21 Antagonists
PT1531850E (en) 2002-06-07 2012-05-07 Zymogenetics Inc Use of il-21 and monoclonal antibody for treating solid cancers
KR20050065590A (en) * 2002-10-11 2005-06-29 노보 노르디스크 에이/에스 Treatment of allergic condition by use of il 21
MXPA05003729A (en) * 2002-10-11 2005-06-17 Novo Nordisk As Treatment of allergic conditions by use of il 21.
KR101098897B1 (en) 2002-12-13 2011-12-26 지모제넥틱스, 인코포레이티드 -21 -21 production in prokaryotic hosts
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
JP2007533298A (en) 2003-10-10 2007-11-22 ノボ　ノルディスク　アクティーゼルスカブ Derivatives of IL-21
WO2005067956A2 (en) * 2004-01-15 2005-07-28 Novo Nordisk A/S Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection
EP1586585A1 (en) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expression system for the production of IL-15/Fc fusion proteins and their use
US20060039902A1 (en) * 2004-08-05 2006-02-23 Young Deborah A Antagonizing interleukin-21 receptor activity
ITRM20040586A1 (en) * 2004-11-29 2005-02-28 Giuliani Spa ANTIGENIC EPITOPES OF INTERLEUCHINA-21, RELATIVE ANTIBODIES AND THEIR USE IN MEDICAL FIELD.
GT200600148A (en) * 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
ATE497975T1 (en) 2005-04-18 2011-02-15 Novo Nordisk As IL-21 VARIANTS
JP5322653B2 (en) 2005-11-28 2013-10-23 ザイモジェネティクス， インコーポレイテッド IL-21 antagonist
AU2006341398B9 (en) 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
AU2007336184A1 (en) 2006-12-21 2008-06-26 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
JP5745274B2 (en) 2007-12-07 2015-07-08 ザイモジェネティクス， インコーポレイテッド Anti-human IL-21 monoclonal antibody
EP2406282A1 (en) * 2009-03-11 2012-01-18 Novo Nordisk A/S Interleukin-21 variants having antagonistic binding to the il-21 receptor
CN102071198A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA for treating psoriasis
CN102071191A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA for treating psoriasis
CN102071192A (en) * 2009-11-20 2011-05-25 中国科学院成都生物研究所 Small interfering RNA used for curing psoriasis
SI2665486T1 (en) * 2011-01-18 2020-07-31 Bioniz, Llc Compositions for modulating gamma-c-cytokine activity
WO2015089217A2 (en) 2013-12-10 2015-06-18 Bionz, Llc Methods of developing selective peptide antagonists
CN105198999A (en) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 Fusion protein and its preparation method and use
WO2017062685A1 (en) 2015-10-09 2017-04-13 Bioniz, Llc Modulating gamma - c -cytokine activity
KR101928981B1 (en) 2016-09-02 2018-12-13 고려대학교 산학협력단 Heterodimeric Fc-fused IL-21 and Pharmaceutical Composition Comprising the Same
CN111205361B (en) 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 Interleukin 21 protein (IL21) mutant and application thereof
WO2020227019A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
WO2023046156A1 (en) * 2021-09-26 2023-03-30 Wuxi Biologics (Shanghai) Co. Ltd. Il-2 variants and fusion proteins thereof

Also Published As

Publication number Publication date
WO2003087320A3 (en) 2004-08-26
AU2003230834A1 (en) 2003-10-27
WO2003087320A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
AU2003230834A8 (en) Antagonists of il-21 and modulation of il-21-mediated t cell responses
PL375691A1 (en) Imidazolopyridines and methods of making and using the same
AU2003295801A8 (en) Modulation of hif1alpha and hif2alpha expression
AU2003288902A8 (en) Microcapsules and methods of use
IL154971A0 (en) Test strip containers and methods of using the same
AU2003281736A8 (en) Electrodes and related devices
AU2003290986A8 (en) Power converter circuitry and method
EP1501514A4 (en) Protein kinase modulators and methods of use
AU2003286657A8 (en) Filters and methods of making and using the same
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
IL154970A0 (en) Test strip containers and methods of using the same
EP1549614A4 (en) Vasculostatic agents and methods of use thereof
AU2003213673A8 (en) Pin1-modulating compounds and methods of use thereof
EP1551398A4 (en) Pyrazolopyridines and methods of making and using the same
EP1497270A4 (en) Amide compounds and methods of using the same
AU2003259717A8 (en) Modulators of rabggt and methods of use thereof
IL166332A0 (en) Isolation and identification of t cells
AU2003233069A8 (en) Gel and powder making
PL375355A1 (en) Novel lipases and uses thereof
SI1558595T1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
IL166467A0 (en) Auto-stimulating cells and method for making and using the same
AU2003211585A1 (en) Reaction cell and method of using the cell
EP1509111A4 (en) Anaerobic tea steeper and method of use
AU2003298020A1 (en) Catalytic antioxidants and methods of use
AU2003242511A1 (en) Methods of evaluating the level of consciousness using aep eeg and anfis

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase